6.2 Tc-99m Bone, Renal, and GU Agents
Key Takeaways
- Tc-99m MDP and HDP bind bone by chemiadsorption to hydroxyapatite; uptake reflects osteoblastic activity and blood flow
- Typical adult bone dose is about 20–30 mCi IV with delayed whole-body imaging at 2–4 hours; hydrate and void to clear soft tissue and bladder
- Tc-99m DTPA measures GFR (filtered); MAG3 is secreted by proximal tubules (effective renal plasma flow–type agent); DMSA binds renal cortex for scarring/morphology
- Extraosseous soft-tissue uptake on bone scan has a differential: renal failure, free Tc, infiltrates, calcifications, tumor, technical errors
- Patient prep for renograms includes hydration, voiding, and appropriate ACE-inhibitor or diuretic (furosemide) protocols when ordered
6.2 Tc-99m Bone, Renal, and GU Agents
Quick Answer: MDP/HDP → bone via chemiadsorption to hydroxyapatite (~20–30 mCi, image 2–4 h). DTPA → GFR filtration; MAG3 → tubular secretion; DMSA → cortical binding for scars. Always link agent → physiology → indication, and know extraosseous bone-scan causes.
Bone Scintigraphy: MDP and HDP
Mechanism
Tc-99m medronate (MDP) and Tc-99m oxidronate (HDP) are diphosphonates. After IV injection they clear from blood, are filtered by the kidneys, and bind to bone mineral by chemiadsorption onto hydroxyapatite, especially in regions of high osteoblastic activity and blood flow. They do not primarily label osteoclasts or pure lytic non-reactive lesions—purely destructive lesions may be cold or subtle until a reactive rim forms.
| Agent | Full name / note | Mechanism | Typical adult dose |
|---|---|---|---|
| MDP | Medronate | Chemiadsorption to bone mineral | ~20–30 mCi (740–1110 MBq) IV |
| HDP | Oxidronate | Same class; often slightly higher bone-to-soft-tissue | ~20–30 mCi IV |
Indications
- Metastatic survey (prostate, breast, lung, and other osteoblastic-prone cancers)
- Occult fracture, stress fracture, shin splints vs fracture patterns
- Osteomyelitis vs cellulitis (three-phase bone scan)
- Prosthesis loosening/infection workups (often with complementary studies)
- Paget disease, reflex sympathetic dystrophy patterns, metabolic bone disease surveys
Protocol Essentials
Administration: IV. Delay: whole-body or spot delayed images typically 2–4 hours after injection (pediatric timing and doses weight-based). Three-phase study: flow (dynamic), blood pool (immediate), and delayed bone phase—for infection/trauma questions.
Prep: hydrate; void immediately before imaging to reduce bladder artifact over pelvis; remove metal; note recent surgery, trauma, or dental work. SPECT/SPECT-CT improves spine and complex anatomy specificity.
Extraosseous Soft-Tissue Uptake — High-Yield Differential
Exam favorites ask why soft tissue is hot on a “bone” scan:
| Finding / cause | Mechanism / note |
|---|---|
| Renal failure / poor clearance | Prolonged soft-tissue and blood-pool activity |
| Free Tc-99m pertechnetate | Stomach, thyroid, salivary activity; kit QC or prep error |
| Injection infiltrate | Focal soft-tissue hot spot at injection site |
| Urine contamination | Clothing, skin—wash and re-image |
| Soft-tissue calcification | Myositis ossificans, calcific tendinitis, mucinous mets |
| Amyloid, hypercalcemia patterns | Soft-tissue microcalcification binding |
| Pleural effusion / ascites | Tracer in fluid collections |
| Tumor (e.g., some breast, liver mets) | Extraosseous diphosphonate uptake |
| Breast / tumor implants artifacts | Attenuation or uptake patterns |
| Radiopharmaceutical impurity / colloid formation | Liver/spleen visualization |
Liver-spleen visualization on a bone kit often means colloid or hydrolyzed reduced Tc, not normal MDP biodistribution—flag radiopharmacy/QC issues.
Renal and GU Agents: Match Physiology to Tracer
| Agent | Localization mechanism | Functional readout | Typical adult dose (order of magnitude) | Primary indications |
|---|---|---|---|---|
| Tc-99m DTPA | Glomerular filtration | GFR estimation; renogram | ~5–10 mCi (185–370 MBq) | GFR, obstruction (with diuretic), renal blood flow patterns |
| Tc-99m MAG3 (mertiatide) | Tubular secretion (proximal tubule) | Effective renal plasma flow–type curve; excellent extraction | ~5–10 mCi | Renography, obstruction, transplant, poor renal function (preferred over DTPA when function low) |
| Tc-99m DMSA (succimer) | Cortical binding (proximal tubular cells) | Morphology, relative function, scars | ~1–5 mCi (often lower) | Pyelonephritis scars, cortical defects, differential function |
DTPA — Filtration
Tc-99m DTPA is filtered by glomeruli with negligible tubular secretion/reabsorption in standard teaching. Clearance approximates GFR when technique is good. Dynamic renogram curves show uptake and excretion. With furosemide (Lasix) challenge, washout distinguishes mechanical obstruction from dilated non-obstructed systems. With ACE-inhibitor (captopril) renography (protocol-specific), look for functionally significant renovascular hypertension patterns.
Limitation: low GFR → poor extraction and noisy curves; many labs prefer MAG3 in compromised kidneys.
MAG3 — Tubular Secretion
Tc-99m mertiatide (MAG3) is extracted mainly by proximal tubular secretion, so first-pass extraction is higher than DTPA. Images are prettier at low function; renograms for obstruction, transplant perfusion/function, and differential uptake are common. Still used with diuretic or ACE-inhibitor protocols when ordered.
QC trap: radiochemical purity and light-sensitive kit handling per package insert; free Tc or impurities alter background.
DMSA — Cortex
Tc-99m DMSA binds to renal cortex. Image 2–4 hours after injection for scars and relative cortical function—not a first-line dynamic obstruction agent. SPECT may help. Pediatric GU infection workups are classic use cases.
Do not confuse: DMSA = morphology/scars; MAG3/DTPA = dynamic function/excretion.
Shared Renal Prep and Pitfalls
- Hydration and empty bladder (catheter if needed) for accurate drainage curves.
- Time diuretic relative to protocol (F+0, F+20, etc.).
- Hold ACE inhibitors or give captopril only as protocol dictates—wrong med timing invalidates captopril studies.
- Infiltrated dose destroys quantitative renography.
- Know left vs right differential function pitfalls (ROI drawing, background subtraction, overlying activity).
GU-Related Notes
Bladder activity on bone scans is expected; residual urine can hide pelvic lesions—post-void images help. Vesicoureteral reflux can be studied with radionuclide cystography (often Tc-99m sulfur colloid or DTPA per lab)—know that reflux studies are a different protocol family from DMSA cortical scans.
Comparison Snapshot
| Task | Best Tc-99m choice among this group |
|---|---|
| Whole-body osteoblastic mets | MDP or HDP |
| Three-phase osteomyelitis | MDP/HDP |
| GFR-oriented renogram | DTPA |
| Renogram when function is poor | MAG3 |
| Cortical scar mapping | DMSA |
For Domain III items, first ask “filtration, secretion, cortical binding, or bone mineral?”—the agent almost chooses itself once physiology is clear.
Which pairing of renal radiopharmaceutical and primary localization mechanism is correct?
A technologist notes intense liver and spleen activity on a Tc-99m MDP bone scan. What is the most likely technical explanation?
For suspected cortical renal scarring after pyelonephritis, which agent and general imaging approach is most appropriate?